Shionogi & Co. Ltd.

10/21/2021 | Press release | Distributed by Public on 10/20/2021 20:30

Notice Regarding the Progress of Phase 2/3 Clinical Trial for New Formulation of COVID-19 Recombinant Protein-based Vaccine